Beacon Medical Interchange

beaconmedic.com

 

Beacon Medical Interchange
Avatar

Adj. Docetaxel for Int. or High Risk Prostate Cancer After Rad: ASCO 2018 GU Highlights

By Beacon Medical Interchange FEATURING Daniel Goldstein
By Beacon Medical Interchange FEATURING Daniel Goldstein
182 views
November 2, 2018
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, ...
read more ↘
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Prostate
01:35
Beacon Medical Interchange

Adj. Docetaxel for Int. or High Risk Prostate Cancer After Rad: ASCO…

Feat. D. Goldstein
02:47
Beacon Medical Interchange

What is Positive Predictive Value of PET PSMA in Prostate Cancer? AS…

Feat. D. Goldstein
03:03
Beacon Medical Interchange

New PARP Inhibitor Abiraterone Combo in Met Prostate Cancer: ASCO 20…

Feat. D. Goldstein
02:03
Beacon Medical Interchange

PROSTVAC Vaccine Therapy for Advanced Prostate Cancer? ASCO 2018 GU …

Feat. D. Goldstein
01:09
Beacon Medical Interchange

Is More Better with Radium-223 for Metastatic Prostate Cancer? ASCO …

Feat. D. Goldstein
02:18
Beacon Medical Interchange

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: ASCO…

Feat. D. Goldstein